Medical - Instruments & Supplies
Compare Stocks
4 / 10Stock Comparison
WRBY vs EYE vs NVST vs HSIC
Revenue, margins, valuation, and 5-year total return — side by side.
Specialty Retail
Medical - Equipment & Services
Medical - Distribution
WRBY vs EYE vs NVST vs HSIC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Specialty Retail | Medical - Equipment & Services | Medical - Distribution |
| Market Cap | $3.34B | $1.81B | $4.04B | $8.09B |
| Revenue (TTM) | $891M | $1.99B | $2.81B | $13.18B |
| Net Income (TTM) | $1M | $30M | $68M | $398M |
| Gross Margin | 53.4% | 56.5% | 55.1% | 29.1% |
| Operating Margin | -0.7% | 3.0% | 9.0% | 5.8% |
| Forward P/E | 56.7x | 32.6x | 17.2x | 13.3x |
| Total Debt | $233M | $695M | $1.71B | $3.69B |
| Cash & Equiv. | $286M | $39M | $1.21B | $156M |
WRBY vs EYE vs NVST vs HSIC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| Warby Parker Inc. (WRBY) | 100 | 51.3 | -48.7% |
| National Vision Hol… (EYE) | 100 | 40.2 | -59.8% |
| Envista Holdings Co… (NVST) | 100 | 58.1 | -41.9% |
| Henry Schein, Inc. (HSIC) | 100 | 92.6 | -7.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: WRBY vs EYE vs NVST vs HSIC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
WRBY is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 13.0%, EPS growth 107.7%, 3Y rev CAGR 13.4%
- 13.0% revenue growth vs HSIC's 4.0%
- +68.3% vs HSIC's +5.9%
EYE is the clearest fit if your priority is income & stability.
- Dividend streak 2 yrs, beta 1.62
NVST is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.65, Low D/E 55.0%, current ratio 2.38x
HSIC carries the broadest edge in this set and is the clearest fit for long-term compounding and valuation efficiency.
- 5.3% 10Y total return vs NVST's -13.1%
- PEG 4.21 vs NVST's 11.53
- Beta 0.73, current ratio 1.38x
- Lower P/E (13.3x vs 17.2x), PEG 4.21 vs 11.53
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 13.0% revenue growth vs HSIC's 4.0% | |
| Value | Lower P/E (13.3x vs 17.2x), PEG 4.21 vs 11.53 | |
| Quality / Margins | 3.0% margin vs WRBY's 0.2% | |
| Stability / Safety | Beta 0.73 vs WRBY's 2.22 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +68.3% vs HSIC's +5.9% | |
| Efficiency (ROA) | 3.6% ROA vs WRBY's 0.2%, ROIC 7.1% vs -1.3% |
WRBY vs EYE vs NVST vs HSIC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
WRBY vs EYE vs NVST vs HSIC — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HSIC leads in 2 of 6 categories
NVST leads 1 • WRBY leads 1 • EYE leads 1 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
NVST leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HSIC is the larger business by revenue, generating $13.2B annually — 14.8x WRBY's $891M. Profitability is closely matched — net margins range from 3.0% (HSIC) to 0.2% (WRBY). On growth, EYE holds the edge at +15.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $891M | $2.0B | $2.8B | $13.2B |
| EBITDAEarnings before interest/tax | $32M | $153M | $342M | $1.1B |
| Net IncomeAfter-tax profit | $1M | $30M | $68M | $398M |
| Free Cash FlowCash after capex | $39M | $73M | $220M | $561M |
| Gross MarginGross profit ÷ Revenue | +53.4% | +56.5% | +55.1% | +29.1% |
| Operating MarginEBIT ÷ Revenue | -0.7% | +3.0% | +9.0% | +5.8% |
| Net MarginNet income ÷ Revenue | +0.2% | +1.5% | +2.4% | +3.0% |
| FCF MarginFCF ÷ Revenue | +4.4% | +3.7% | +7.8% | +4.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +8.3% | +15.1% | +14.4% | +7.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +7.5% | +111.3% | +130.0% | +14.9% |
Valuation Metrics
HSIC leads this category, winning 6 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, HSIC trades at a 99% valuation discount to WRBY's 2076.3x P/E. Adjusting for growth (PEG ratio), HSIC offers better value at 6.84x vs NVST's 58.08x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $3.3B | $1.8B | $4.0B | $8.1B |
| Enterprise ValueMkt cap + debt − cash | $3.3B | $2.5B | $4.5B | $11.6B |
| Trailing P/EPrice ÷ TTM EPS | 2076.34x | 61.70x | 86.73x | 21.56x |
| Forward P/EPrice ÷ next-FY EPS est. | 56.75x | 32.60x | 17.21x | 13.26x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 58.08x | 6.84x |
| EV / EBITDAEnterprise value multiple | 73.08x | 16.20x | 13.28x | 10.87x |
| Price / SalesMarket cap ÷ Revenue | 3.83x | 0.91x | 1.49x | 0.61x |
| Price / BookPrice ÷ Book value/share | 9.25x | 2.12x | 1.32x | 1.79x |
| Price / FCFMarket cap ÷ FCF | 76.32x | 24.68x | 17.54x | 14.12x |
Profitability & Efficiency
HSIC leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
HSIC delivers a 8.2% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $0 for WRBY. NVST carries lower financial leverage with a 0.55x debt-to-equity ratio, signaling a more conservative balance sheet compared to EYE's 0.80x. On the Piotroski fundamental quality scale (0–9), EYE scores 7/9 vs HSIC's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +0.4% | +3.5% | +2.2% | +8.2% |
| ROA (TTM)Return on assets | +0.2% | +1.5% | +1.2% | +3.6% |
| ROICReturn on invested capital | -1.3% | +3.0% | +4.8% | +7.1% |
| ROCEReturn on capital employed | -1.0% | +3.8% | +4.9% | +9.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 | 7 | 4 |
| Debt / EquityFinancial leverage | 0.63x | 0.80x | 0.55x | 0.77x |
| Net DebtTotal debt minus cash | -$53M | $656M | $496M | $3.5B |
| Cash & Equiv.Liquid assets | $286M | $39M | $1.2B | $156M |
| Total DebtShort + long-term debt | $233M | $695M | $1.7B | $3.7B |
| Interest CoverageEBIT ÷ Interest expense | — | 3.54x | 12.76x | 4.59x |
Total Returns (Dividends Reinvested)
WRBY leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HSIC five years ago would be worth $8,746 today (with dividends reinvested), compared to $4,462 for EYE. Over the past 12 months, WRBY leads with a +68.3% total return vs HSIC's +5.9%. The 3-year compound annual growth rate (CAGR) favors WRBY at 31.0% vs NVST's -11.3% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +20.2% | -12.0% | +12.0% | -8.2% |
| 1-Year ReturnPast 12 months | +68.3% | +46.3% | +44.2% | +5.9% |
| 3-Year ReturnCumulative with dividends | +125.0% | +2.2% | -30.3% | -11.7% |
| 5-Year ReturnCumulative with dividends | -50.1% | -55.4% | -46.6% | -12.5% |
| 10-Year ReturnCumulative with dividends | -50.1% | -18.0% | -13.1% | +5.3% |
| CAGR (3Y)Annualised 3-year return | +31.0% | +0.7% | -11.3% | -4.0% |
Risk & Volatility
Evenly matched — WRBY and HSIC each lead in 1 of 2 comparable metrics.
Risk & Volatility
HSIC is the less volatile stock with a 0.73 beta — it tends to amplify market swings less than WRBY's 2.22 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. WRBY currently trades 87.7% from its 52-week high vs EYE's 76.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.22x | 1.62x | 1.65x | 0.73x |
| 52-Week HighHighest price in past year | $31.00 | $30.02 | $30.42 | $89.29 |
| 52-Week LowLowest price in past year | $14.96 | $14.38 | $16.33 | $61.95 |
| % of 52W HighCurrent price vs 52-week peak | +87.7% | +76.0% | +79.8% | +79.0% |
| RSI (14)Momentum oscillator 0–100 | 46.6 | 40.8 | 55.1 | 39.1 |
| Avg Volume (50D)Average daily shares traded | 2.8M | 1.4M | 2.4M | 1.2M |
Analyst Outlook
EYE leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: WRBY as "Buy", EYE as "Buy", NVST as "Hold", HSIC as "Hold". Consensus price targets imply 54.2% upside for EYE (target: $35) vs 7.8% for WRBY (target: $29).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $29.33 | $35.20 | $27.00 | $86.43 |
| # AnalystsCovering analysts | 15 | 14 | 19 | 32 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 2 | — | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.2% | +4.1% | +10.5% |
HSIC leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). NVST leads in 1 (Income & Cash Flow). 1 tied.
WRBY vs EYE vs NVST vs HSIC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is WRBY or EYE or NVST or HSIC a better buy right now?
For growth investors, Warby Parker Inc.
(WRBY) is the stronger pick with 13. 0% revenue growth year-over-year, versus 4. 0% for Henry Schein, Inc. (HSIC). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate Warby Parker Inc. (WRBY) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — WRBY or EYE or NVST or HSIC?
On trailing P/E, Henry Schein, Inc.
(HSIC) is the cheapest at 21. 6x versus Warby Parker Inc. at 2076. 3x. On forward P/E, Henry Schein, Inc. is actually cheaper at 13. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Henry Schein, Inc. wins at 4. 21x versus Envista Holdings Corp's 11. 53x.
03Which is the better long-term investment — WRBY or EYE or NVST or HSIC?
Over the past 5 years, Henry Schein, Inc.
(HSIC) delivered a total return of -12. 5%, compared to -55. 4% for National Vision Holdings, Inc. (EYE). Over 10 years, the gap is even starker: HSIC returned +5. 3% versus WRBY's -50. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — WRBY or EYE or NVST or HSIC?
By beta (market sensitivity over 5 years), Henry Schein, Inc.
(HSIC) is the lower-risk stock at 0. 73β versus Warby Parker Inc. 's 2. 22β — meaning WRBY is approximately 203% more volatile than HSIC relative to the S&P 500. On balance sheet safety, Envista Holdings Corp (NVST) carries a lower debt/equity ratio of 55% versus 80% for National Vision Holdings, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — WRBY or EYE or NVST or HSIC?
By revenue growth (latest reported year), Warby Parker Inc.
(WRBY) is pulling ahead at 13. 0% versus 4. 0% for Henry Schein, Inc. (HSIC). On earnings-per-share growth, the picture is similar: National Vision Holdings, Inc. grew EPS 202. 8% year-over-year, compared to 7. 2% for Henry Schein, Inc.. Over a 3-year CAGR, WRBY leads at 13. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — WRBY or EYE or NVST or HSIC?
Henry Schein, Inc.
(HSIC) is the more profitable company, earning 3. 0% net margin versus 0. 2% for Warby Parker Inc. — meaning it keeps 3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVST leads at 8. 3% versus -0. 6% for WRBY. At the gross margin level — before operating expenses — NVST leads at 55. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is WRBY or EYE or NVST or HSIC more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Henry Schein, Inc. (HSIC) is the more undervalued stock at a PEG of 4. 21x versus Envista Holdings Corp's 11. 53x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Henry Schein, Inc. (HSIC) trades at 13. 3x forward P/E versus 56. 7x for Warby Parker Inc. — 43. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EYE: 54. 2% to $35. 20.
08Which pays a better dividend — WRBY or EYE or NVST or HSIC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is WRBY or EYE or NVST or HSIC better for a retirement portfolio?
For long-horizon retirement investors, Henry Schein, Inc.
(HSIC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 73)). Warby Parker Inc. (WRBY) carries a higher beta of 2. 22 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HSIC: +5. 3%, WRBY: -50. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between WRBY and EYE and NVST and HSIC?
These companies operate in different sectors (WRBY (Healthcare) and EYE (Consumer Cyclical) and NVST (Healthcare) and HSIC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.